Acceder

Bibliografías temáticas / Liquid biopsy / Artículos de revistas

Siga este enlace para ver otros tipos de publicaciones sobre el tema: Liquid biopsy.

Artículos de revistas sobre el tema "Liquid biopsy"

Autor: Grafiati

Publicado: 4 de junio de 2021

Última modificación: 7 de julio de 2024

Crea una cita precisa en los estilos APA, MLA, Chicago, Harvard y otros

Elija tipo de fuente:

Consulte los 50 mejores artículos de revistas para su investigación sobre el tema "Liquid biopsy".

Junto a cada fuente en la lista de referencias hay un botón "Agregar a la bibliografía". Pulsa este botón, y generaremos automáticamente la referencia bibliográfica para la obra elegida en el estilo de cita que necesites: APA, MLA, Harvard, Vancouver, Chicago, etc.

También puede descargar el texto completo de la publicación académica en formato pdf y leer en línea su resumen siempre que esté disponible en los metadatos.

Explore artículos de revistas sobre una amplia variedad de disciplinas y organice su bibliografía correctamente.

1

Singh, Pratibha, Meenakshi Gothwal y Garima Yadav. "Liquid Biopsy in Ovarian Cancer". Indian Journal of Obstetrics and Gynecology 6, n.º 4 (2018): 427–31. http://dx.doi.org/10.21088/ijog.2321.1636.6418.16.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

2

Jain, Amit Kumar, Guruprasad Bhat, Vineet Govinda Gupta y Hari Goyal. "Liquid Biopsy". Indian Journal of Medical and Paediatric Oncology 42, n.º 01 (marzo de 2021): 077–79. http://dx.doi.org/10.1055/s-0041-1729434.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

3

Goodwin, Peter M. "Liquid Biopsy". Oncology Times 38, n.º 13 (julio de 2016): 40. http://dx.doi.org/10.1097/01.cot.0000489521.34002.61.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

4

Siddiqua, Umme Iffat. "Liquid Biopsy". KYAMC Journal 10, n.º 1 (22 de mayo de 2019): 1. http://dx.doi.org/10.3329/kyamcj.v10i1.41473.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

5

Gingras, Isabelle, Roberto Salgado y Michail Ignatiadis. "Liquid biopsy". Current Opinion in Oncology 27, n.º 6 (noviembre de 2015): 560–67. http://dx.doi.org/10.1097/cco.0000000000000223.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

6

Lavine, M. S. "Liquid Biopsy". Science 328, n.º 5975 (8 de abril de 2010): 141. http://dx.doi.org/10.1126/science.328.5975.141-a.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

7

Hekmat, K. y C. Bruns. "„Liquid biopsy“". Der Chirurg 90, S2 (13 de febrero de 2019): 120. http://dx.doi.org/10.1007/s00104-019-0845-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

8

Hekmat, K. y C. Bruns. "„Liquid biopsy“". Der Chirurg 88, n.º 7 (14 de junio de 2017): 621. http://dx.doi.org/10.1007/s00104-017-0458-4.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

9

Fulmer, Tim. "Liquid biopsy". Science-Business eXchange 5, n.º 26 (junio de 2012): 668. http://dx.doi.org/10.1038/scibx.2012.668.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

10

Imyanitov, E. N., E. Sh Kuligina y G. A. Janus. "LIQUID BIOPSY IN CLINICAL ONCOLOGY". Practical oncology 23, n.º 4 (30 de diciembre de 2022): 211–24. http://dx.doi.org/10.31917/2304211.

Texto completo

Resumen

Liquid biopsy is the analysis of tumor fragments (entire cells, nucleic acids,proteins) in hysiological and pathological body liquids. This technology has already been included in standard procedures of detecting secondary mutations, which are associate with acquired drug resistance. Liquid biopsy is a promising tool for early cancer detection, evaluation of the success of radical cancer surgery, monitoring of residual tumor disease, assessment of treatment efficacy etc.

Los estilos APA, Harvard, Vancouver, ISO, etc.

11

Ranuncolo, Stella Maris. "Liquid Biopsy in Liquid Tumors". Journal of Cancer Therapy 08, n.º 03 (2017): 302–20. http://dx.doi.org/10.4236/jct.2017.83026.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

12

R, Dr Kalyani. "Liquid Biopsy : An emerging concept for diagnosis and management of cancer". JOURNAL OF CLINICAL AND BIOMEDICAL SCIENCES 09, n.º 4 (15 de diciembre de 2019): 91–96. http://dx.doi.org/10.58739/jcbs/v09i4.4.

Texto completo

Resumen

Tumour diagnosis is conventionally done by radiological findings and invasive surgical biopsy. Of late non-invasive technique where blood sample, urine and body fluids are used to extract circulating tumour cells (CTC) and genetic material for cancer diagnosis and treatment which is called as “Liquid Biopsy”.1,2 In this technique the liquid sample is used to isolate CTC, circulating tumour DNA (ctDNA), RNA, Exosomes and proteins which are shed by tumour cells into blood circulation, body fluids or urine in most of the cancers depending on the site of the can-cer. This technique enables non-invasive profiling of solid tumours, the results which can be comparable with that of tissue biopsy.3,4,5,6,7 As tissue biopsy is single biopsy, it gives only spatially and temporary snap shot of genetic makeup of cancer tissue unlike liquid biopsy, where samples can be taken at repeated intervals and it reveals the dynamic and heterogenei-ty of the cancer tissue.[8] Originally liquid biopsy was used to analyze CTC. At present it mainly analyzes ctDNA. However CTC and ctDNA are complementary technologies which can be used in parallel. As ctDNA is a potential surrogate for the entire tumour genome, it is many times referred as “Liquid Biopsy”.9,10 The different components of liquid biopsy are CTC, ctDNA, RNA, Exosomes, Proteins and Platelets.

Los estilos APA, Harvard, Vancouver, ISO, etc.

13

Trombetta, Domenico, Angelo Sparaneo, Federico Pio Fabrizio y Lucia Anna Muscarella. "Liquid biopsy and NSCLC". Lung Cancer Management 5, n.º 2 (junio de 2016): 91–104. http://dx.doi.org/10.2217/lmt-2016-0006.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

14

Ronvaux, Lorian, Matteo Riva, An Coosemans, Marielle Herzog, Guillaume Rommelaere, Nathalie Donis, Lionel D’Hondt y Jonathan Douxfils. "Liquid Biopsy in Glioblastoma". Cancers 14, n.º 14 (13 de julio de 2022): 3394. http://dx.doi.org/10.3390/cancers14143394.

Texto completo

Resumen

Glioblastoma (GBM) is the most common and aggressive primary brain tumor. Despite recent advances in therapy modalities, the overall survival of GBM patients remains poor. GBM diagnosis relies on neuroimaging techniques. However, confirmation via histopathological and molecular analysis is necessary. Given the intrinsic limitations of such techniques, liquid biopsy (mainly via blood samples) emerged as a non-invasive and easy-to-implement alternative that could aid in both the diagnosis and the follow-up of GBM patients. Cancer cells release tumoral content into the bloodstream, such as circulating tumor DNA, circulating microRNAs, circulating tumor cells, extracellular vesicles, or circulating nucleosomes: all these could serve as a marker of GBM. In this narrative review, we discuss the current knowledge, the advantages, and the disadvantages of each circulating biomarker so far proposed.

Los estilos APA, Harvard, Vancouver, ISO, etc.

15

Banys-Paluchowski, Maggie, Natalia Krawczyk y Tanja Fehm. "Liquid Biopsy beim Mammakarzinom". Senologie - Zeitschrift für Mammadiagnostik und -therapie 18, n.º 04 (diciembre de 2021): 365–76. http://dx.doi.org/10.1055/a-1678-1129.

Texto completo

Resumen

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

Los estilos APA, Harvard, Vancouver, ISO, etc.

16

Banys-Paluchowski, Maggie, Natalia Krawczyk y Tanja Fehm. "Liquid Biopsy beim Mammakarzinom". TumorDiagnostik & Therapie 42, n.º 05 (31 de mayo de 2021): 361–72. http://dx.doi.org/10.1055/a-1467-0165.

Texto completo

Resumen

ZusammenfassungIn den letzten Jahren gewinnt die Liquid Biopsy, d. h. die blutbasierte Untersuchung von zirkulierenden Tumorzellen (CTCs) und Nukleinsäuren (DNA/RNA) beim Mammakarzinom zunehmend an Relevanz. Zahlreiche Studien haben bereits die hohe prognostische Bedeutung der CTC-Detektion sowohl im frühen als auch metastasierten Stadium gezeigt. Des Weiteren korrelieren die Veränderungen der CTC-Zahlen und der zirkulierenden Tumor-DNA (ctDNA) im Verlauf der Erkrankung mit dem Ansprechen auf die Therapie. Im Fokus der Forschung stehen derzeit die Liquid-Biopsy-basierten Therapieinterventionen beim metastasierten Mammakarzinom. In diesem Kontext wurde Alpelisib, ein PI3K-Inhibitor, als erste Substanz durch die FDA und die EMA zugelassen.

Los estilos APA, Harvard, Vancouver, ISO, etc.

17

Rossi, Davide, Valeria Spina, Alessio Bruscaggin y Gianluca Gaidano. "Liquid biopsy in lymphoma". Haematologica 104, n.º 4 (7 de marzo de 2019): 648–52. http://dx.doi.org/10.3324/haematol.2018.206177.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

18

Poulet, Geoffroy, Joséphine Massias y Valerie Taly. "Liquid Biopsy: General Concepts". Acta Cytologica 63, n.º 6 (2019): 449–55. http://dx.doi.org/10.1159/000499337.

Texto completo

Resumen

Liquid biopsy provides the opportunity of detecting, analyzing and monitoring cancer in various body effluents such as blood or urine instead of a fragment of cancer tissue. It is composed of different biological matrices such as circulating tumor cells (CTCs), cell free nucleic acids, exosomes or tumors “educated platelets.” In addition to representing a non- or minimally invasive procedure, it should represent a better view of tumor heterogeneity and allows for real-time monitoring of cancer evolution. Recent technological and molecular advances, greatly facilitated by the use of microfluidics in many cases, have permitted large progresses both in our ability to purify and analyze liquid biopsy components. In particular, the great developments of droplet-based digital PCR and the various optimizations of next generation sequencing technologies are central to the several validations of CTC-free DNA as a strong cancer biomarker. However, complete adoption of liquid biopsy in clinics will require pursuing recent efforts in the standardization of procedures both on the pre-analytical and analytical aspects.

Los estilos APA, Harvard, Vancouver, ISO, etc.

19

Wu, Lingling, Yidi Wang, Lin Zhu, Yilong Liu, Teng Wang, Dan Liu, Yanling Song y Chaoyong Yang. "Aptamer-Based Liquid Biopsy". ACS Applied Bio Materials 3, n.º 5 (11 de febrero de 2020): 2743–64. http://dx.doi.org/10.1021/acsabm.9b01194.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

20

Wakelee, H. "PC 03.03 Liquid Biopsy". Journal of Thoracic Oncology 12, n.º 11 (noviembre de 2017): S1666—S1667. http://dx.doi.org/10.1016/j.jtho.2017.09.197.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

21

Salinas-Sánchez, A. S., C. Martínez-Sanchís, J. M. Giménez-Bachs y D. C. García-Olmo. "Liquid biopsy in cancer". Actas Urológicas Españolas (English Edition) 40, n.º 1 (enero de 2016): 1–2. http://dx.doi.org/10.1016/j.acuroe.2015.11.001.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

22

Stone, Louise. "Biomarkers from liquid biopsy". Nature Reviews Urology 13, n.º 8 (19 de julio de 2016): 434. http://dx.doi.org/10.1038/nrurol.2016.133.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

23

Behrend, Christian. "Liquid Biopsy beim Kolonkarzinom". Im Focus Onkologie 21, n.º 3 (marzo de 2018): 15–16. http://dx.doi.org/10.1007/s15015-018-3816-2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

24

red. "Therapiekontrolle durch Liquid Biopsy". Info Onkologie 19, n.º 8 (diciembre de 2016): 37. http://dx.doi.org/10.1007/s15004-016-5528-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

25

Reimers, Natalie, Claudia Hille y Klaus Pantel. "Aktuelles zur Liquid Biopsy". InFo Onkologie 21, S1 (junio de 2018): 24–29. http://dx.doi.org/10.1007/s15004-018-6134-0.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

26

Harbour, J. William. "Liquid Biopsy in Retinoblastoma". JAMA Ophthalmology 135, n.º 11 (1 de noviembre de 2017): 1231. http://dx.doi.org/10.1001/jamaophthalmol.2017.4094.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

27

Voelker, Rebecca. "Liquid Biopsy Receives Approval". JAMA 316, n.º 3 (19 de julio de 2016): 260. http://dx.doi.org/10.1001/jama.2016.8833.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

28

Eibl, Robert H. y Markus Schneemann. "Liquid biopsy and glioblastoma". Exploration of Targeted Anti-tumor Therapy 4, n.º 1 (26 de febrero de 2023): 28–41. http://dx.doi.org/10.37349/etat.2023.00121.

Texto completo

Resumen

Glioblastoma is the most common and malignant primary brain tumor. Despite a century of research efforts, the survival of patients has not significantly improved. Currently, diagnosis is based on neuroimaging techniques followed by histopathological and molecular analysis of resected or biopsied tissue. A recent paradigm shift in diagnostics ranks the molecular analysis of tissue samples as the new gold standard over classical histopathology, thus correlating better with the biological behavior of glioblastoma and clinical prediction, especially when a tumor lacks the typical hallmarks for glioblastoma. Liquid biopsy aims to detect and quantify tumor-derived content, such as nucleic acids (DNA/RNA), circulating tumor cells (CTCs), or extracellular vesicles (EVs) in biofluids, mainly blood, cerebrospinal fluid (CSF), or urine. Liquid biopsy has the potential to overcome the limitations of both neuroimaging and tissue-based methods to identify early recurrence and to differentiate tumor progression from pseudoprogression, without the risks of repeated surgical biopsies. This review highlights the origins and time-frame of liquid biopsy in glioblastoma and points to recent developments, limitations, and challenges of adding liquid biopsy to support the clinical management of glioblastoma patients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

29

Ilié, Marius y Paul Hofman. "Pros: Can tissue biopsy be replaced by liquid biopsy?" Translational Lung Cancer Research 5, n.º 4 (agosto de 2016): 420–23. http://dx.doi.org/10.21037/tlcr.2016.08.06.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

30

Corcoran, Ryan B. "Liquid biopsy versus tumor biopsy for clinical-trial recruitment". Nature Medicine 26, n.º 12 (23 de noviembre de 2020): 1815–16. http://dx.doi.org/10.1038/s41591-020-01169-6.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

31

Saini, Aman, Yash Pershad, Hassan Albadawi, Malia Kuo, Sadeer Alzubaidi, Sailendra Naidu, M.-Grace Knuttinen y Rahmi Oklu. "Liquid Biopsy in Gastrointestinal Cancers". Diagnostics 8, n.º 4 (29 de octubre de 2018): 75. http://dx.doi.org/10.3390/diagnostics8040075.

Texto completo

Resumen

Liquid biopsy is the sampling of any biological fluid in an effort to enrich and analyze a tumor’s genetic material. Peripheral blood remains the most studied liquid biopsy material, with circulating tumor cells (CTC’s) and circulating tumor DNA (ctDNA) allowing the examination and longitudinal monitoring of a tumors genetic landscape. With applications in cancer screening, prognostic stratification, therapy selection and disease surveillance, liquid biopsy represents an exciting new paradigm in the field of cancer diagnostics and offers a less invasive and more comprehensive alternative to conventional tissue biopsy. Here, we examine liquid biopsies in gastrointestinal cancers, specifically colorectal, gastric, and pancreatic cancers, with an emphasis on applications in diagnostics, prognostics and therapeutics.

Los estilos APA, Harvard, Vancouver, ISO, etc.

32

Cheung, Alvin Ho-Kwan, Chit Chow y Ka-Fai To. "Latest development of liquid biopsy". Journal of Thoracic Disease 10, S14 (junio de 2018): S1645—S1651. http://dx.doi.org/10.21037/jtd.2018.04.68.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

33

Stickeler, Elmar. "Urindiagnostik – die neue Liquid Biopsy". Der Gynäkologe 54, n.º 3 (4 de febrero de 2021): 175–80. http://dx.doi.org/10.1007/s00129-021-04749-w.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

34

Zmarzły, Nikola, Ewelina Hermyt, Andrzej Witek, Joanna Gola y Urszula Mazurek. "Liquid biopsy in endometrial cancer". Current Gynecologic Oncology 17, n.º 1 (31 de julio de 2019): 27–42. http://dx.doi.org/10.15557/cgo.2019.0004.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

35

AKIN KABALAK, Pinar y Ulku YILMAZ. "Liquid Biopsy in Lung Cancer". Güncel Göğüs Hastalıkları Serisi 6, n.º 3 (4 de agosto de 2020): 18–22. http://dx.doi.org/10.5152/gghs.2018.036.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

36

Eibl, Robert H. y Markus Schneemann. "Liquid biopsy for monitoring medulloblastoma". Extracellular Vesicles and Circulating Nucleic Acids 3, n.º 3 (2022): 263–74. http://dx.doi.org/10.20517/evcna.2022.36.

Texto completo

Resumen

Despite recent progress in molecular diagnostics defining four distinct medulloblastoma groups, the clinical management of these malignant childhood tumors of the cerebellum remains challenging. After surgical removal of the tumor, both cytotoxic chemotherapy and irradiation can offer additional curative benefits, but they also include a significant risk of long-term damage. Early molecular profiling aims to predict the outcome of such aggressive therapies. This prevents unnecessary damage to patients who may not need it and helps to identify those patients with remaining tumor cells who may benefit from more aggressive treatment with the intent to cure. Monitoring tumor evolution in real time allows personalized precision medicine with an immediate clinical response resulting in a better outcome. Liquid biopsy includes various methodologies already applied in numerous studies and clinical trials for common cancers including brain tumors, but information on medulloblastomas is limited. This review summarizes the recent developments of how liquid biopsy can support or even replace the standard monitoring of medulloblastomas by medical imaging or cytology and discusses what will be needed to make liquid biopsy a new gold standard in diagnosis, therapy, and follow-up of medulloblastomas for the benefit of the patients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

37

Sahoo, TapanKumar. "Liquid biopsy in oncology practice". Oncology Journal of India 2, n.º 3 (2018): 45. http://dx.doi.org/10.4103/oji.oji_32_18.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

38

Ranade, A. A., A. Bhatt, Darshana Patil, Indu Patwal, D. B. Akolkar, D. A. Joshi, P. P. Patil, R. R. Dasare, T. D. Bhangale y Y. R. Jha. "Liquid biopsy in periampullary carcinoma". International Journal of Molecular and Immuno Oncology 1, n.º 1 (25 de noviembre de 2016): 45. http://dx.doi.org/10.18203/issn.2456-3994.intjmolimmunooncol20164388.

Texto completo

Resumen

<p style="margin: 0in 0in 8pt 0.25in; text-align: justify;">Periampullary cancers are rare tumors arising within 2 cm of the major papilla of the duodenum. In this case report, we describe the use of liquid biopsy to analyze cell-free tumor DNA and exosomal microRNA to guide treatment selection in a patient with periampullary adenocarcinoma. To our knowledge, this is the first time such case report has been described in the literature.</p>

Los estilos APA, Harvard, Vancouver, ISO, etc.

39

Pankaj, Sangeeta. "Liquid biopsy in ovarian carcinoma". Journal of Indira Gandhi Institute Of Medical Sciences 7, n.º 2 (2021): 79. http://dx.doi.org/10.4103/jigims.jigims_47_21.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

40

Mahdi, Ahmed. "LIQUID BIOPSY- A NEW PROSPECT". Iraqi Journal of Medical Sciences 16, n.º 4 (31 de diciembre de 2018): 353–56. http://dx.doi.org/10.22578/ijms.16.4.1.

Texto completo

Resumen

Tissue biopsy has been the mainstay in tumor diagnosis for centuries. But due to its invasiveness and the heterogeneity of tumors there was a need for an alternative or adjuvant techniques to diagnose and assess tumors. Liquid biopsy is emerging as a new technique that will open the way for the diagnosis, tumor characterization, assess disease prognosis and individualize treatment options in cancer patients. Keywords:Biopsy, CTC, ctDNA Citation: Mahdi AK. Liquid biopsy - A new prospect. Iraqi JMS. 2018; 16(4): 353-356. doi: 10.22578/IJMS.16.4.1

Los estilos APA, Harvard, Vancouver, ISO, etc.

41

Ueda, Koji. "Cancer liquid biopsy using exosomes". Electrophoresis Letters 61, n.º 2 (2017): 65–68. http://dx.doi.org/10.2198/electroph.61.65.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

42

Lousada-Fernandez, Fatima, Oscar Rapado-Gonzalez, Jose-Luis Lopez-Cedrun, Rafael Lopez-Lopez, Laura Muinelo-Romay y Maria Suarez-Cunqueiro. "Liquid Biopsy in Oral Cancer". International Journal of Molecular Sciences 19, n.º 6 (8 de junio de 2018): 1704. http://dx.doi.org/10.3390/ijms19061704.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

43

Santise, G., D. Maselli, C. Mignogna, K. PIrrone, V. Mollace, G. Donato y N. Malara. "RF41 LIQUID BIOPSY FORCARDIAC TUMORS". Journal of Cardiovascular Medicine 19 (noviembre de 2018): e77. http://dx.doi.org/10.2459/01.jcm.0000550086.27815.c2.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

44

Lissa, Delphine y Ana I. Robles. "Methylation analyses in liquid biopsy". Translational Lung Cancer Research 5, n.º 5 (octubre de 2016): 492–504. http://dx.doi.org/10.21037/tlcr.2016.10.03.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

45

Holzhauer, Peter. "Liquid Biopsy – Diagnostik mit Januskopf?" Deutsche Zeitschrift für Onkologie 51, n.º 02 (junio de 2019): 57. http://dx.doi.org/10.1055/a-0865-8451.

Texto completo

Resumen

Die manchmal unfassbaren und grenzenlos anmutenden Einblicke in die molekulare Individualität eines jeden von uns wurden in den letzten Jahren durch rasante Fortschritte im Bereich innovativer molekulargenetischer Untersuchungsmethoden, wie Next Generation Sequencing möglich.

Los estilos APA, Harvard, Vancouver, ISO, etc.

46

Reddi, Honey. "Current Applications for Liquid Biopsy". Clinical OMICs 5, n.º 1 (enero de 2018): 11. http://dx.doi.org/10.1089/clinomi.05.01.10.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

47

Zhang, Hui-Juan, Xin-Hui Fang y Jian Li. "Liquid biopsy in colorectal cancer". World Chinese Journal of Digestology 26, n.º 3 (28 de enero de 2018): 182–89. http://dx.doi.org/10.11569/wcjd.v26.i3.182.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

48

Benka, Stephen G. "Macrophages in a liquid biopsy". Physics Today 67, n.º 5 (mayo de 2014): 16–17. http://dx.doi.org/10.1063/pt.3.2373.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

49

Shankar, Ganesh M., Leonora Balaj, Shannon L. Stott, Brian Nahed y Bob S. Carter. "Liquid biopsy for brain tumors". Expert Review of Molecular Diagnostics 17, n.º 10 (6 de septiembre de 2017): 943–47. http://dx.doi.org/10.1080/14737159.2017.1374854.

Texto completo

Los estilos APA, Harvard, Vancouver, ISO, etc.

50

Pisapia, Pasquale, Umberto Malapelle y Giancarlo Troncone. "Liquid Biopsy and Lung Cancer". Acta Cytologica 63, n.º 6 (19 de diciembre de 2018): 489–96. http://dx.doi.org/10.1159/000492710.

Texto completo

Resumen

The identification of non-small cell lung cancer (NSCLC) patients potentially responsive to targeted therapies relies on a number of relevant biomarkers, including EGFR, ALK, ROS-1, and PD-L1. Biomarker identification is most commonly based on surgical sample collection. However, when tissues are difficult to reach or when multiple analyses are necessary to monitor tumor progression and treatment response, liquid biopsy is a valid noninvasive alternative. This analysis, which is preferentially performed on circulating tumor DNA (ctDNA) extracted from plasma samples, has the major advantage of reducing the inherent risks and discomfort of tissue biopsy. However, a major disadvantage is that it yields only a low number of ctDNA targets. Thus, to avoid false-positive and false-negative results, it is important to adopt and validate technologies with high sensitivity and specificity in the pre-analytical phase of sampling. This review succinctly addresses the principal methodologies for analyzing plasma-derived ctDNA in NSCLC patients.

Los estilos APA, Harvard, Vancouver, ISO, etc.

Ofrecemos descuentos en todos los planes premium para autores cuyas obras están incluidas en selecciones literarias temáticas. ¡Contáctenos para obtener un código promocional único!